744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296) von Lee, J-M., MacLaughlan, S., Matei, D., Song, M., Brubaker, L., Rimmel, B., Eskander, R.N., Kyi, C., Williams, H., Duska, L., Musa, F., Coleman, R.L., Slomovitz, B.M., Gamelin, E.C., Cuillerot, J-M., Phadnis, M.M., Guercio, B., Crafton, S., Konstantinopoulos, P.

Volltext

Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma von Noel, M., Lowery, M., Ryan, D., Wolpin, B., Bullock, A., Britten, C., Jin, B., Ganguly, B.J., Taylor, C.T., Yin, D., Wunderlich, D.A., Gamelin, E.C., Linehan, D.C.

Volltext